Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Lawrence F Eichenfield

33PUBLICATIONS
106CO-AUTHORS
Disease surveillanceInfant and child healthTraditional Chinese medicine and treatmentsAdolescent healthMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

Sort by Publication Date:
|Jun 11, 2026
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

|Mar 08, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE).

Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz

|Feb 08, 2026
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United States.

Jonathan I Silverberg, David Cohen, Emma Guttman-Yassky

|Apr 20, 2025
Patient-Reported Impact of Atopic Dermatitis on Pediatric and Adolescent Patients With Moderate-To-Severe Disease: Results of a Real-World, Cross-Sectional Survey.

Lawrence F Eichenfield, Vivian Y Shi, JiaDe Yu

|Feb 27, 2025
ROCKET: a phase 3 program evaluating the efficacy and safety of rocatinlimab in moderate-to-severe atopic dermatitis.

Emma Guttman-Yassky, Eric Simpson, Robert Bissonnette

|Feb 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial.

Lawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati

Pageof 6

Frequent Collaborators

5 joint publications

Erin Almaraz

4 joint publications

Emma Guttman-Yassky

4 joint publications

Jonathan I Silverberg

3 joint publications

Daniel Sturm

3 joint publications

Adelaide A Hebert

3 joint publications

Elaine Siegfried

2 joint publications

Robert Bissonnette

2 joint publications

Irene Lara-Corrales

2 joint publications

Katrina Abuabara

2 joint publications

Jusleen Ahluwalia

Frequent Collaborators

5 joint publications

Erin Almaraz

4 joint publications

Emma Guttman-Yassky

4 joint publications

Jonathan I Silverberg

3 joint publications

Daniel Sturm